Shares of Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) soared over 5% on Thursday after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.
For Q3 2024, Arcutis Biotherapeutics posted revenue of $44.8 million, up 17% from the year-ago period. The company's net loss narrowed to $41.5 million, or $0.33 per share, compared to a net loss of $44.6 million, or $0.72 per share, in Q3 2023.
Arcutis exceeded analysts' expectations for both revenue and earnings per share. Revenue surpassed estimates by 20%, while EPS beat forecasts by 21%. Looking ahead, the company's revenue is projected to grow at an average annual rate of 35% over the next three years, outpacing the 21% growth forecast for the U.S. biotechnology industry.
The strong quarterly performance and positive outlook have fueled a rally in Arcutis Biotherapeutics' stock, which has gained around 25% over the past week. Investors appear to be taking an optimistic view on the company's prospects, driven by its robust revenue growth and improving profitability.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。